New therapy with XLQ ® to suppress chronic prostatitis through its anti‐inflammatory and antioxidative activities

Author:

Yang Feiya1,Meng Lingquan23,Han Panpan4,Chen Dexi56,Wang Mingshuai3,Jiang Yongguang7,Wu Yanqiao8,Wu Yiling8,Xing Nianzeng13ORCID

Affiliation:

1. Department of Urology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China

2. Department of Urology Qianfoshan Hospital Shandong University Jinan P. R. China

3. Department of Urology Beijing Chaoyang Hospital Capital Medical University Beijing P. R. China

4. Department of Hematology Qilu Hospital Shandong University Jinan P. R. China

5. Department of Hepatology, Beijing You'an Hospital Capital Medical University Beijing P. R. China

6. Department of Hepatology, Beijing Institute of Hepatology Beijing P. R. China

7. Department of Urology Beijing Anzhen Hospital Capital Medical University Beijing P. R. China

8. National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine Shijiazhuang Yiling Pharmaceutical Co., Ltd Shijiazhuang P. R. China

Funder

This research was financially supported by the Capital Science and Technology Leading Talent Project

Capital Science and Technology Leading Talent Project

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3